YULAREB 150 MG 42 TABLET
Condition : New
0
From UAE
To United States
in 5-10 days
Description
YULAREB (belantamab mafodotin-blmf) is a medication used to treat relapsed or refractory multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Here’s an overview:
Pros:
- Novel Mechanism of Action: YULAREB is an antibody-drug conjugate (ADC) that targets B-cell maturation antigen (BCMA), a protein found on the surface of multiple myeloma cells. It delivers a cytotoxic agent directly to the cancer cells, causing cell death.
- Efficacy in Relapsed or Refractory Multiple Myeloma: Clinical trials have shown that YULAREB can induce responses in patients with relapsed or refractory multiple myeloma who have received prior treatment with other therapies.
- Convenient Administration: YULAREB is administered by intravenous infusion once every three weeks, which may be more convenient for patients compared to daily oral medications or frequent hospital visits.
- Potential for Improved Outcomes: By targeting BCMA, YULAREB offers a targeted approach to treating multiple myeloma, potentially leading to improved outcomes compared to conventional chemotherapy.
- Side Effects: Common side effects of YULAREB may include corneal events (such as keratopathy or blurred vision), thrombocytopenia (low platelet count), and infusion-related reactions. Some side effects may be severe and require dose adjustments or discontinuation of treatment.
- Risk of Ocular Toxicity: YULAREB can cause ocular toxicity, including changes in vision, which may be reversible upon discontinuation of the medication. Regular ophthalmologic monitoring is recommended during treatment.
- Cost: YULAREB can be expensive, especially for those without adequate insurance coverage. The price can vary depending on factors such as location and insurance plan.